Soleno Therapeutics (SLNO) Liabilities and Shareholders Equity (2013 - 2026)

Soleno Therapeutics (SLNO) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $608.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 91.26% year-over-year to $608.4 million; the TTM figure through Mar 2026 stood at $2.1 billion (up 68.37% YoY), while the FY2025 annual figure was $563.8 million, up 70.36% from the prior year.
• Liabilities and Shareholders Equity grew to $608.4 million in Q1 2026 per SLNO's latest filing, from $563.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $608.4 million in Q1 2026 and bottomed at $19.5 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $232.7 million across 5 years, with a median of $180.7 million in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 54.08% — and 2024, when it soared 882.84%.
• Soleno Therapeutics' Liabilities and Shareholders Equity stood at $26.5 million in 2022, then jumped by 581.93% to $180.7 million in 2023, then soared by 83.17% to $331.0 million in 2024, then jumped by 70.36% to $563.8 million in 2025, then advanced by 7.9% to $608.4 million in 2026.
• Business Quant data shows SLNO's Liabilities and Shareholders Equity at $608.4 million in Q1 2026, $563.8 million in Q4 2025, and $599.9 million in Q3 2025.